Brief: Fusen Pharmaceutical Announces Capital Injection Deal Into Jiangxi Kangde
24/12/2019 11:30
Dec 24 (Reuters) - Fusen Pharmaceutical Company Ltd
1652.HK :
* HUBEI ZHONGBANG HENGTAI PHARMACEUTICAL TECHNOLOGY TO
INJECT
CAPITAL OF RMB50.2 MILLION TO JIANGXI KANGDE FOR A 29.9% STAKE
* DUE TO CAPITAL INJECTION, CLOUD DOLLAR'S STAKE IN JIANGXI
KANGDE
WILL BE DILUTED FROM 51% TO ABOUT 35.8%
Source text for Eikon: ID:nHKSbR4jzw
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA